外周血中miR-34b表达水平对Ⅲb～Ⅳ期NSCLC患者靶向治疗效果及预后的评估价值分析OACSTPCD
Evaluation of the Expression Level of miR-34b in Peripheral Blood for Targeted Treatment Effect and Prognosis in Stage Ⅲb-Ⅳ NSCLC Patients
目的:探究外周血中微小 RNA-34b(miR-34b)表达水平对Ⅲb～Ⅳ非小细胞肺癌(NSCLC)患者靶向治疗效果及预后的评估价值.方法:选取 2020 年 1 月至 2022 年 1 月于我院接受靶向治疗的104 例NSCLC患者作为研究对象,根据靶向治疗效果分为有效组(n=40)及无效组(n=64).所有患者治疗后均接受1 年随访,根据预后情况分为生存组(n=32)及死亡组(n=72).实时定量PCR检测外周血中miR-34b,采用受试者工作特征曲线(ROC)分析外周血 miR-34b 表达水平对Ⅲb～Ⅳ期NSCLC患者靶向治疗效果及预后的评估价值,采用Kaplan-Meier生存曲线分析不同外周血miR-34b表达水平与Ⅲb～Ⅳ期NSCLC患者预后的关系.结果:有效组外周血 miR-34b 表达水平高于无效组(P<0.05);ROC曲线显示,外周血miR-34b 表达水平评估Ⅲb～Ⅳ期 NSCLC 患者靶向治疗效果的 AUC 为0.856(P<0.05);存活组外周血miR-34b表达水平高于死亡组(P<0.05);ROC 曲线显示,外周血miR-34b表达水平评估Ⅲb～Ⅳ期NSCLC患者预后的AUC为0.916(P<0.05);Log-rank检验显示,miR-34b>2.16 组和miR-34b≤2.16 组患者生存率比较,差异有统计学意义(P<0.05).结论:外周血miR-34b表达水平与Ⅲb～Ⅳ期NSCLC患者靶向治疗效果及预后有关,检测外周血 miR-34b 表达水平有助于评估靶向治疗效果及预后.
Objective:To explore the evaluation value of peripheral blood microRNA-34b(miR-34b)for targeted therapy effect and prognosis in patients with stage Ⅲb-Ⅳ non-small cell lung cancer(NSCLC).Methods:A total of 104 NSCLC patients who received targeted treatment from January 2020 to January 2022 were selected.According to the efficacy of targeted treatment,they were divided into the effective group(n= 40)and ineffective group(n=64).All patients were followed up for one year,and based on the prognosis,they were divided into the survival group(n=32)and death group(n=72).Real-time quantitative PCR was used to detect miR-34b in peripheral blood.The receiver operating characteristic curve(ROC)was employed to analyze the evaluation value of peripheral blood miR-34b expression level for the targeted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients.Kaplan-Meier survival curve analysis was used to explore the relationship between different peripheral blood miR-34b expression levels and the prognosis of stage Ⅲb-ⅣNSCLC patients.Results:The peripheral blood miR-34b expression level in the effective group was higher than that in the ineffective group(P<0.05).The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the targeted treatment effect of stage Ⅲb-Ⅳ NSCLC patients was 0.856(P<0.05).The peripheral blood miR-34b expression level in the survival group was higher than that in the death group(P<0.05).The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the prognosis of stage Ⅲb-Ⅳ NSCLC patients was 0.916(P<0.05).The Log-rank test showed a statistically significant difference in survival rate between the miR-34b>2.16 group and miR-34b≤2.16 group(P<0.05).Conclusion:The expression level of peripheral blood miR-34b is associated with the targe-ted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients.Detecting the expression level of peripher-al blood miR-34b is helpful for evaluating the targeted treatment effect and prognosis.
张亚鹏;任玉川;刘昭;吕晓燕;李永利
山西省阳泉市第一人民医院肿瘤血液内科,山西 阳泉 045000山西省肿瘤医院呼吸一病区,山西 太原 030013
非小细胞肺癌微小RNA-34b靶向治疗
Non-small cell lung cancermiRNA-34bTargeted treatment
《河北医学》 2024 (001)
45-49 / 5
山西省医学科技创新团队项目,(编号:2020TD15)
评论